LONDON, June 18 GlaxoSmithKline's (GSK.L)
cervical cancer vaccine Cervarix was picked as the medicine of
choice for the British Department of Health's immunisation
program, the drugmaker said on Wednesday.
The program aims to protect against the two types of human
papillomavirus responsible for about 70 percent of cervical
cancers and starts in September for girls aged 12 to 13, the
The decision marks a defeat for Merck's (MRK.N) Gardasil,
which competes with the Glaxo drug.
(Reporting by Michael Kahn)